Podcasts about Chemical biology

Minister for Further and Higher Education, Research, Innovation and Science, James Lawless TD, has today announced a €17.7 million investment in nine research infrastructure projects through Research Ireland's Research Infrastructure Programme. The awards will contribute to the advancement of high-quality and high-impact research activities across Ireland. Announcing the funding, Minister Lawless commented: "This targeted investment in research infrastructure will help to future-proof the conducting of high-quality research endeavours across our higher education institutions and in a wide range of disciplines. It is important for researchers to be equipped with the innovative tools and the conducive environments that can help deliver research excellence and impact." In welcoming the announcement, Celine Fitzgerald, Interim Chief Executive of Research Ireland, said: "The Research Infrastructure Programme supports the research community in building and sustaining cutting-edge infrastructure to accomplish high-quality, impactful, and innovative research. The programme encourages partnerships and collaboration between different cohorts of researchers in Ireland, across academia and enterprise." Nine Irish research infrastructure projects The nine funded projects are: Coastal & Offshore ASV (Autonomous Surface Vehicle), University of Limerick, led by Prof. Gerard Dooly, aims to acquire a coastal and offshore autonomous surface vehicle (ASV) with a length of 9 meters and a range of 2500 nautical miles. This will enhance Ireland's marine science capabilities, bridge data gaps, and improve our understanding of ocean habitats. (€1,851,784) Cryo Electron Microscopy Unit National Platform, University College Dublin, led by Prof. Oliver Blacque, will establish a cryo-EM unit for high-resolution 3D visualisation of biological structures, aiding various biomedical research applications. (€3,749,322) NMR Centre of Expertise, Trinity College Dublin, led by Prof. Mathias Senge, will provide advanced NMR techniques for chemistry research, including a multi-channel 600MHz NMR and a 400MHz instrument for high-throughput analyses. (€2,649,497) Photon Counting CT for Cardiovascular and Oncology Research, Trinity College Dublin, led by Prof. James Meaney, will expand imaging capabilities with a Photon-counting CT scanner for advanced medical imaging in oncology and cardiovascular research. (€2,721,339) National Enteric Methane Mitigation Testbed, Teagasc, led by Dr Stephen Butler, will develop strategies to reduce methane emissions from ruminant animals, contributing to climate change mitigation. (€1,983,502) Characterising Earth Materials using Multi-Sensor Core Logger Analysis (Earth SCAn), University College Dublin, led by Prof. Peter Haughton, will advance the characterisation of Earth materials for interdisciplinary research into climate change, energy, and geohazards. (€600,113) Advanced Material Characterisation and Imaging Platform, Dublin City University, led by Dr Karsten Fleischer, will enhance material analysis capabilities with X-ray photoelectron spectroscopy (XPS) for various applications in ICT, energy, and medical devices. (€2,251,897) C-Trap: A Dynamic Single Molecule Platform for Chemical Biology and Biophysics, Dublin City University, led by Prof. Andrew Kellett, will enable single-molecule analysis for understanding molecular mechanisms of diseases, aiding biopharmaceutical and therapeutic research. (€948,901) Automated X-ray Photoelectron Spectroscopy (XPS), University College Dublin, led by Prof. Eoin Casey, will replace aging XPS equipment to enhance surface analysis capabilities for various research and industry applications. (€986,952) The awardees are from the following research bodies: University of Limerick (UL), University College Dublin (UCD), Trinity College Dublin (TCD), Teagasc, and Dublin City University (DCU). See more breaking stories here.

When we invest our hard-earned money, we naturally seek a financial return—but could there be other rewards as well?Faith-based investing offers more than just financial gains. Today, Finny Kuruvilla joins us to explore the deeper impact of aligning our investments with our values.Dr. Finny Kuruvilla serves as a Co-Chief Investment Officer, Senior Portfolio Manager, and founding member of Eventide Asset Management, an underwriter of Faith & Finance. He holds an M.D. from Harvard Medical School, a Ph.D. in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry.Common Objections to Faith-Based InvestingIndeed, Christians might have different views on some of these, but here are three of the most common that Finny hears consistently:Objection 1: “I'm not responsible for the actions of the companies I invest in.”Many investors assume that purchasing stocks or mutual funds does not connect them to a company's actions. However, investing is ownership. When you purchase shares in a company—whether publicly traded or private—you become a partial owner.If you owned a small business and that business engaged in unethical practices, it would reflect on you. The same principle applies to publicly traded companies. As shareholders, we are tied to the actions and values of the companies we invest in.Objection 2: “What difference can I make? These companies are too big.”Some argue that individual investors cannot influence large corporations. However, history shows that even a small percentage of engaged investors can shape corporate values—just like voting in an election, where small margins can determine the outcome.Through shareholder engagement, faith-driven investors can influence corporate decision-making. Large companies respond to shareholder resolutions, and when values-aligned investors unite, they can steer businesses toward ethical practices.Objection 3: “Faith-based investing means I'll underperform financially.”A common concern is that limiting investment choices to faith-aligned companies will lead to lower returns. However, research suggests otherwise.Companies with strong ethical foundations—those that treat employees well, operate with integrity, and provide valuable goods and services—tend to outperform over the long term. Businesses that exploit customers or employees may see short-term gains but often struggle in the long run. Faith-based investing is not just morally sound—it's also financially strategic.The Three Benefits of Faith-Based Investing 1. Integrity: Investing with a Clear ConscienceThe foundation of faith-based investing is the principle of loving our neighbor. Jesus taught us to treat others as we want to be treated (Luke 6:31), and this applies to business and investing as well.Proverbs 1 warns against pursuing “ill-gotten gain,” or wealth that exploits others. Many mainstream funds include companies engaged in tobacco, gambling, and unethical labor practices.Investing with integrity means choosing companies that:Provide valuable goods and servicesTreat employees fairlyOperate with transparency and ethical leadershipBusiness should be about supplying goods and services—not exploiting people. Faith-based investing ensures that we support businesses that contribute to human flourishing.2. Impact: The Power of Faith-Driven InvestorsOne of the most compelling reasons for faith-based investing is the ability to make a real impact. History provides powerful examples of how Christian investors have shaped industries and social policies.A notable case is the role of Christian investors in ending apartheid in South Africa. In the 1970s, a group of faith-driven investors partnered with Reverend Leon Sullivan to pressure corporations like Ford and General Motors to implement anti-apartheid policies within their workplaces. These shareholder resolutions sparked a domino effect, leading other companies to follow suit.This example demonstrates that investors—when united and strategic—can drive significant cultural and ethical change. Today, faith-driven investors have opportunities to:Encourage companies to uphold biblical values in business operationsAvoid investing in industries that profit from addiction, exploitation, or human sufferingPromote corporate social responsibility by engaging in shareholder activism3. Performance: Ethical Investing Can Lead to Strong ReturnsMany assume that avoiding certain industries—such as gambling, pornography, or companies that oppose Christian values—means sacrificing returns. However, data suggests that companies with strong ethical principles actually perform better over time.Most investors define total return as:Share price return + dividend returnHowever, a biblical perspective expands total return to include:Financial return + integrity + impactInvesting in companies that operate with integrity and long-term vision leads to sustainable growth and reduced risk. Ethical companies that treat employees well, focus on quality products, and manage resources wisely often outperform businesses prioritizing short-term profits over long-term stability.How to Get Started with Faith-Based InvestingFor many believers, the idea of faith-aligned investing is a brand-new concept. They strive to honor God in spending, giving, and career choices, but they haven't considered how their investments align with their faith.Here's how to begin:Use screening tools—Many financial platforms provide tools to evaluate how investments align with Christian values. Work with faith-driven investment professionals—Christian financial advisors and fund managers can guide you toward biblically responsible portfolios. You can find a Certified Kingdom Advisor (CKA) when you go to FaithFi.com and click "Find a Professional." Explore faith-based funds—Several firms specialize in faith-aligned investments. Eventide is one of many great options available. To find a complete list of faith-based investment funds and companies, visit faithandinvesting.com/faithfi.  Pray for wisdom—Ask God to guide your financial decisions, ensuring that your investments honor Him and advance His kingdom.Faith-based investing is more than a financial strategy—it's a movement. As more believers align their financial decisions with their faith, they contribute to a marketplace that reflects God's heart for justice, integrity, and human flourishing.When investors choose integrity, prioritize impact, and trust that God honors ethical investing, they participate in kingdom work that extends beyond their own lifetime.If you're ready to take the next step, learn more at EventideFunds.com. Faith-based investing isn't just about returns—it's about stewardship that glorifies God and blesses others.On Today's Program, Rob Answers Listener Questions:My wife and I inherited a house from a family member, and it's out of state. We would like to keep it and use it for friends and family, but we don't want to rent it out. What are your thoughts on this situation?Resources Mentioned:Faithful Steward: FaithFi's New Quarterly MagazineEventide Asset ManagementWisdom Over Wealth: 12 Lessons from Ecclesiastes on Money (Pre-Order)Look At The Sparrows: A 21-Day Devotional on Financial Fear and AnxietyRich Toward God: A Study on the Parable of the Rich FoolFind a Certified Kingdom Advisor (CKA) or Certified Christian Financial Counselor (CertCFC)FaithFi App Remember, you can call in to ask your questions most days at (800) 525-7000. Faith & Finance is also available on the Moody Radio Network and American Family Radio. Visit our website at FaithFi.com where you can join the FaithFi Community and give as we expand our outreach.

During the last decade, advances in genome editing and pluripotent stem cell (PSC) culture have let researchers generate edited PSC lines to study a wide variety of biological questions. However, abnormalities in cell lines such as aneuploidy, mutations, on-target and off-target editing errors, and microbial contamination can arise during PSC culture or due to undesired editing outcomes. To ensure valid experimental results and the safety of PSC-derived therapeutics, it is important to detect these abnormalities and choose PSC lines without them. Existing quality control methods typically focus on detecting one type of abnormality. Whole genome sequencing is an all-in-one detection method for any abnormality involving changes to DNA sequences but until now it has required considerable computational expertise. Today's guests will discuss a new computational tool, SeqVerify, that analyzes short-read WGS data for quality control of wild-type or edited PSCs. The platform provides an end-to-end analysis framework that can be a valuable quality control method for researchers working with PSCs, and more broadly, for cell line quality control in general. GuestsGeorge Church, PhD Harvard University, Harvard Medical School, Massachusetts Institute of Technology, and Wyss Harvard Institute. Merrick Smela, PhD, Department of Chemistry and Chemical Biology, Harvard University. HostMartin Pera, Editor-in-Chief, Stem Cell Reports and The Jackson LaboratoryX: @martinperaJAXSupporting Content SeqVerify: An accessible analysis tool for cell line genomic integrity, contamination, and gene editing outcomes, Stem Cell ReportsAbout Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians.X: @StemCellReportsAbout ISSCRWith nearly 5,000 members from more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.ISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsMegan Koch, Marketing ManagerJack Mosher, Scientific AdvisorHunter Reed, Senior Marketing CoordinatorVoice WorkBen Snitkoff

We're joined in this episode by Dr. Sarah Barry, Reader in Chemical Biology at King's College London. Sarah started with an interest in biochemistry, went into organic chemistry because it was more concrete, and now applies her chemist's approach to understanding and manipulating biosynthesis of natural products for important areas of research, including antibiotics. This insightful conversation gives a peek into the mind of a chemical biologist's way of thinking about and approaching challenges that span biology and chemistry. We learn about the historical challenges of discovering and synthesizing natural products, but we then hear about how innovations in molecular biology are allowing researchers to revisit this field with a new approach. Sarah and her team identify and manipulate genes, express and purify proteins in the lab, and then characterize those enzymes for their abilities to drive biocatalytic transformations that are beyond challenging using traditional organic or inorganic chemistry approaches. Our conversation spans from the details of the molecular biology methods used, to the high-level applications being explored in this research, all with an ease that only someone this interdisciplinary could do. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Download Transcripts: Speaking of Mol Bio Podcast | Thermo Fisher Scientific - US Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology.

Dr. Dionna Williams is an Autistic and first-generation academic and martial artist. Dionna received their MSc and PhD from the Albert Einstein College of Medicine and completed her postdoctoral training at Johns Hopkins University. Dionna has received many prestigious academic fellowships and awards for her research accomplishments and commitment to diversifying academic medicine. She is currently an Associate Professor of Pharmacology and Chemical Biology at Emory University where their research interests center on the intersection of HIV and substance use, focusing on identifying immunologic and pharmacologic means to increase the neurologic health of people living with HIV. While Dionna amassed academic and professional accomplishments they struggled with what she once considered to be a collection of seemingly unrelated quirks and social discomfort. While Dionna was always aware of these differences, they became less of a hindrance to interacting with people as she learned to suppress the things that made her most different from others. However, these strategies eventually became less effective and at the most stressful time of their life Dionna began therapy. It was through this experience that they received an autism diagnosis at the age of 35, which has been life changing. Since this realization one and a half years ago, Dionna realized all the ways in which she lived an inauthentic life and they are now committed to living a life of their own accord, unmasked, and open about the joys and challenges faced as a neurodivergent scientist from a low-income background raising the most amazing 3-year old.  3 ways you can support the podcast and the work we do... Become a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠member⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, champion or partner and join our growing community. Buy us a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠coffee.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rate & review⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ the show or an episode Thank you to our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Community Partners ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠who are supporting the work that we are doing. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠A Tidy Mind⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Growth Pod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Hormones On The Blink ⁠⁠⁠⁠⁠ The Late Discovered Club is hosted by Catherine Asta and edited by Caty Ava - visit our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ www.thelatediscoveredclub.com Contact ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Catherine Asta⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Music by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Allora⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on ⁠⁠⁠Instagram⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Join our October Post Discovery Support Circle⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Join 'The Relational Space'⁠⁠⁠ Circle ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Asta Community of Professionals⁠⁠⁠

“For we are his workmanship, created in Christ Jesus for good works, which God prepared beforehand, that we should walk in them.” - Ephesians 2:10Our good works are not for our sake but for God's sake, to give Him glory. Investing gives us a powerful way to do that. Today, we'll talk with Dr. Finny Kuruvilla about investing to change the world.Dr. Finny Kuruvilla is the Co-Chief Investment Officer and Founding Member of Eventide Asset Management, an underwriter of Faith & Finance. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry.The Purpose of InvestingInvesting has always been about supplying capital to businesses. This concept originated in the 1400s and 1500s with the rise of corporations, particularly those financing maritime trade. Investing primarily aims to fund companies to help them do good work. However, this purpose can be perverted to support businesses that go against God's design for humanity. Hence, it's crucial to remember that investing should always aim to fund ethical companies.Investing as OwnershipWhen you invest, you become a part-owner of a company, which carries an ethical responsibility. Like owning a small business, you are accountable for the actions of the companies you invest in. This ownership confers a duty to ensure these businesses align with your values and promote good.Integrity in InvestingRomans 12:9 states, "Let love be without hypocrisy. Abhor what is evil; cling to what is good." This principle applies to investing as well. To maintain integrity, you should avoid profiting from industries that contradict your values, such as pornography or tobacco. Instead, invest in businesses that advance the common good, like those making significant strides in healthcare and biotechnology.For example, advances in treatments for leukemia have dramatically increased children's survival rates, thanks to innovative companies in the healthcare sector. These companies exemplify how investment capital can drive significant positive outcomes.Performance and OutperformanceInvesting in businesses that promote the common good can lead to long-term outperformance. Studies, like those referenced in Fred Reichheld's "Winning on Purpose" and Alex Edmans' "Grow the Pie," show that companies adding value to their stakeholders often outperform their peers. This approach aligns with the biblical principle of loving your neighbor and can result in superior long-term returns.Eventide's ApproachEventide uses a framework called Business 360 to evaluate how companies interact with various stakeholders, including customers, employees, and the community. By focusing on companies excelling in value creation, Eventide aims to identify businesses aligned with promoting the global common good and likely to outperform over the long term.The future is bright for Faith-Based Investing because of the growing awareness in faith-based and secular circles that investing inherently involves ethical considerations. This awareness will lead to more opportunities to use investment dollars constructively, promoting values that align with a vision for a better world.Investing with integrity means aligning your investments with your values and ethical responsibilities. As Christians, this involves avoiding industries that contradict biblical principles and supporting those that advance the common good. Doing so can achieve both financial returns and a positive global impact. To learn more about this approach to investing, visit Eventide Funds.On Today's Program, Rob Answers Listener Questions:I heard somewhere that you can take 4% a year out of your 401(k)s, and they should last you, but I'm looking for information like that. How much? When do we start taking money from these 401(k)s?I could not file my income taxes on time this year, but I did again and got an extension. Are there any penalties that I need to be aware of? I also have become very lazy regarding budgeting, keeping my finances, and keeping on track with them. How do I start over? Where do I begin?Resources Mentioned:Eventide Asset ManagementWinning on Purpose: The Unbeatable Strategy of Loving Customers by Fred ReichheldGrow the Pie: How Great Companies Deliver Both Purpose and Profit by Alex EdmansRich Toward God: A Study on the Parable of the Rich FoolFind a Certified Kingdom Advisor (CKA) or Certified Christian Financial Counselor (CertCFC)FaithFi App Remember, you can call in to ask your questions most days at (800) 525-7000. Faith & Finance is also available on the Moody Radio Network and American Family Radio. Visit our website at FaithFi.com where you can join the FaithFi Community and give as we expand our outreach.

for the first part of this episode, two extra episodes each month, and exclusive content please visit: patreon.com/thenickbryantpodcast Video: https://youtu.be/a-YZlcfor-I  Dave Collum is the former chair of the Department of Chemistry and Chemical Biology at Cornell University. He is currently the Betty R. Miller Professor of Chemistry at Cornell University. He is also the associate editor of the Journal of Organic Chemistry. https://chemistry.cornell.edu/david-b-collum Twitter @ DavidBCollum nickbryantnyc.com EpsteinJustice.com

for this full episode, two extra episodes each month, and exclusive content please visit: patreon.com/thenickbryantpodcast Dave Collum is the former chair of the Department of Chemistry and Chemical Biology at Cornell University. He is currently the Betty R. Miller Professor of Chemistry at Cornell University. He is also the associate editor of the Journal of Organic Chemistry. https://chemistry.cornell.edu/david-b-collum Twitter @ DavidBCollum nickbryantnyc.com EpsteinJustice.com

In this episode, I had a blast with Professor David B. Collum trying to deconstruct everything happening in the world right now as best we can. River is the Bitcoin exchange of choice for the long-term investor. Use this link to get started and earn up to $100 in BTC when you buy Bitcoin at River. Have you secured your ticket to Bitcoin 2024 in Nashville yet? Don't miss out on this historic event of epic proportions. Use the code "Matrix" at checkout to enjoy a 10% discount on your order. Hurry, visit b.tc/conference now to secure your spot and join us this Thursday Friday and Saturday. Immerse yourself in a world of groundbreaking ideas, insightful discussions, and endless networking opportunities. This is the perfect opportunity to connect with like-minded individuals and learn from the brightest minds in the industry. Don't wait any longer! Get your ticket now and be part of this momentous occasion. Remember to use the code "Matrix" for 10% off your tickets at b.tc/conference. I can't wait to see you there! Dr. David B. Collum, MA, MS, Ph.D. is a Professor at The Cornell University.    He received a Doctor of Philosophy from Columbia University in the City of New York.    His research interests are Chemistry and Chemical Biology, Physical Organic Chemistry, Organolithium Chemistry, Organosodium Chemistry, Kinetics, Reaction Mechanism. Follpw Professor David Collum on Twitter.  Follow Cedric Youngelman on Twitter Follow The Bitcoin Matrix Podcast on Twitter Finally if you could write a five star review for The Bitcoin Matrix Podcast wherever you listen to your podcasts that would really help get the word out and help new listeners find the show. And thank you for listening!

Michelle Manni, PhD, assistant professor of Pharmacology and Chemical Biology at the University of Pittsburgh School of Medicine, discusses challenges often faced by women in academic research or medicine and what institutions can do to support women leaders in this space.

On this episode, I was joined by Alan Stevens and Rumi Young who walk through the contents of the FDA Draft Essential Drug Delivery Outputs for Devices Intended toDeliver Drugs and Biological Products Guidance for Industry. Industry Comments are DUE 9/29/2024. Alan Stevens is the Global Head of Complex Devices and Drug Delivery Systems at AbbVie within the RA Emerging Technologies, Devices and Combination Products team. Prior to joining AbbVie, Alan spent 20 years at the FDA/CDRH leading premarket review and policy development for drug delivery devices and combination products. Rumi Young, Meng, RAC is the Director of Regulatory Policy at Novo Nordisk. Rumi joined Industry from FDA where she spent four years in CDRH's Division of Drug Delivery, General Hospital and Human Factors. As Acting Assistant Director for Injection Devices, her team was responsible for the approval of drug delivery injection devices and combination products such as syringes, auto injectors, pen injectors, on-body injectors and smart connected devices. Prior to FDA Rumi worked at Genentech and AstraZeneca for eight years in combination product development. Rumi has both a Bachelors in Chemistry and Chemical Biology and Masters in Engineering in Material Science from Cornell University.

Join our host, Dr. Paolo Braiuca, as he chats with some of the most fascinating scientists around the globe doing trailblazing work in a variety of fields and industries. Learn about their personal stories, notable contributions, and the enthusiasm for discovery that unites them all. This is a podcast for anyone who wants to learn more about science and the brilliant minds advancing it.Now in the fifth season of our podcast, in store are more inspiring conversations about trending topics with influential guest that chemists, students and science enthusiasts will undoubtedly find captivating. In the mid-season checkpoint, Paolo reflects on the evolution of the series and gives a glimpse of what's to come. Diversity remains a priority but, there will be deeper looks at topics like battery technology, PFAS chemistry, chemical biology, and sustainability in organic chemistry. If you're new to the podcast, now is the time to catch up and get ready for what's to come. If you're a loyal listener, Paolo has a special message for you and a humble request Regardless, we're happy you found us and we're looking forward to sharing more with you soon!Bonus content!Access bonus content curated by each episode's guest by visiting www.thermofisher.com/chemistry-podcast for links to recent publications, podcasts, books, videos and more.View the video of each episode on www.thermofisher.com/chemistry-podcast.A free thank you gift for our listeners! Visit the episode website and request your free Bringing Chemistry to Life t-shirt.Use Podcast Code: Bi0catalys1sin June or LabRatsRul3 in July We read every email so please share your questions and feedback with us! Email helloBCTL@thermofisher.com About Your HostPaolo Braiuca grew up in the North-East of Italy and holds a PhD in Pharmaceutical Sciences from nearby esteemed University of Trieste, Italy. He developed expertise in biocatalysis during his years of post-doctoral research in Italy and the UK, where he co-founded a startup company. With this new venture, Paolo's career shifted from R&D to business development, taking on roles in commercial, product management, and marketing. He has worked in the specialty chemicals, biotechnology, and pharmaceutical markets in Germany and the UK, where he presently resides. He is currently the Director of Global Market Development in the Laboratory Chemicals Division at Thermo Fisher Scientific™ which put him in the host chair of the Bringing Chemistry to Life podcast. A busy father of four, in what little free time he has, you'll find him inventing electronic devices with the help of his loyal 3D-printer and soldering iron. And if you ask him, he'll call himself a “maker” at heart.

Subscribe to Receive Venkat's Weekly Newsletter Christina was involved in a lot of activities in High School. She was at Science Fairs. She was on the Tennis team, quiz bowl. She did choir, theater, acapella, and leadership roles. But Science was her main thing. Christina joins our podcast to share her undergraduate experience at Haverford College, Interest in Research, Winning the Goldwater Scholarship, and Advice for High Schoolers. In particular, we discuss the following with her:  Overall Haverford Experience Natural Product Biosynthesis Research The Goldwater Scholarship Advice to High Schoolers Topics discussed in this episode: Introduction to Christina McBride, Haverford College [] Hi Fives - Podcast Highlights [] Overall Haverford Experience [] Why Haverford? [] High School Interests [] Research in High School [] Transition to College [] Peers & Profs [] Starting UG Research [] The Research [] Research Outcomes [] Applying for Goldwater Scholarship [] Winning The Goldwater Scholarship [] The GW Difference [] Research Impact [] Majoring in Chemistry [] Campus Activities [] Advice for High Schoolers [] Memory [] Our Guest: Christina McBride is a Goldwater Scholar who graduated with a Bachelor's degree in Chemistry from Haverford College in Pennsylvania. Christina is currently pursuing her PhD in Chemical Biology at the University of Michigan Ann Arbor. Memorable Quote: “I can say my main thing is to really explore and to kind of take that jump, even if you feel unprepared, or that you don't necessarily have the skills that other people do, because you want to be able to explore so many different areas. Because even if something is tough, that doesn't mean that it's impossible. ” Christina McBride. Episode Transcript: Please visit Episode's Transcript. Similar Episodes: College Experiences , UG Research Calls-to-action: Follow us on Instagram. To Ask the Guest a question, or to comment on this episode, email podcast@almamatters.io. Subscribe or Follow our podcasts at any of these locations: Apple Podcasts, Spotify.

I've gotten to spend a little bit of time with Rob Shepherd over the years. He's working on soft robotics and all the different kinds of materials advancements that could really help us make robots that are more naturally integrated into the world. Things like polymer colloidal suspensions as inks for 3d printers so they can fabricate microfluidic devices, synthesizing single micron to millimeter scale parts in glass and silicon and all kinds of other stuff, like tiny gears. Imagine if you were trying to make a micro machinery like Swiss watches, but smaller. That's the kind of stuff that he worked on in the past and researched, developing pneumatic actuators, different kinds of elastomers and things that could maybe give us a real kind of muscles for robots. Also developing the kinds of walking and undulating movements that you would want robots to do once they got beyond just being these kind of rigid jerky things that we have now. This also gets really interesting when you're trying to make fingers for robots, which I'm personally obsessed with. I think it is a kingpin that's going to enable robots to start going to all the places they haven't been able to. We've seen some real progress on that lately. Rob is a great guy, super humble, willing to share everything he knows, which is a lot. Rob is an associate professor at the Sibley School of Mechanical and Aerospace Engineering at Cornell university. We recorded this in Ojai, California in a In-n-out Burger, on a Friday night, when it was full of teenagers... So this is it also an exercise in using AI for noise canceling, post-facto. I know it won't be the cleanest recording you've ever heard, but I think it will be interesting to know that we ran the audio through a tool called AUDO, and AUDO is one of many. I don't have anything to do with them. I've talked to the founders few times. I think it's cool. There's probably other ones, I don't know what the best ones are, but I've been using AUDO, and it's able to do this remarkable job cutting out, like a hundred noisy teenagers, while Rob and I are just sitting there eating burgers, talking about robots. So hopefully you'll learn something from that as well... Important Links: Cornell University Organic Robotic Labs Llume Cornell Engineering Robotics and Autonomy Advanced Manufacturing and Materials About Rob Shepherd Rob Shepherd received his B.S. (2002) and Ph.D. (2010) in Material Science at the University of Illinois where his research focused on developing polymeric and colloidal suspensions as 'inks' for 3D printers. He also fabricated microfluidic devices to synthesize single micron to millimeter scale parts. Concurrently to performing this research, he received his M.B.A. (2009) at U of I and started a company, worked with several other startups, and gained significant experience with the details of market research, financials, accounting issues, and legal aspects of entrepreneurship. In 2010, he continued his education as a post-doctoral fellow at Harvard University in George Whitesides's research group in the Department of Chemistry and Chemical Biology. In this group, he developed pneumatic actuators in soft elastomers that took the form of a machine capable of moving in multiple gaits: walking and undulating. These actuators have also been used for low-cost manipulators, and in concert with a microfluidic system for biomimetic camouflage & display.

David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.

Laura Kiessling is the Novartis Professor of Chemistry at Massachusetts Institute of Technology (MIT). In this episode of Back of the Napkin, beginning in Laura's art-adorned office at MIT, the conversation explores her journey from a small Wisconsin town to the pinnacles of scientific research and education at MIT.Laura's professional trajectory is a testament to her passion for science — from her top performance in a university chemistry class to her inspired transfer to MIT following a serendipitous spring break encounter with women doing amazing science in Boston. Her curiosity about the unknown and desire to push boundaries in chemistry led her to explore the intricate world of carbohydrates and their profound impact on diseases such as tuberculosis. Laura has advised approximately 100 graduate students and postdoctorates and emphasizes that the essence of scientific progress is distilled not only through individual brilliance but also through the profound impact of community, collaboration, and mentorship. Laura is not only a proponent but a role model for women in science, advocating for equal representation, mentorship, and recognition. Her narrative is punctuated with instances where she challenged the norms and paved the way for others to follow.Links:Lessons in Chemistry Book: https://bit.ly/3wCnTGSPublication - Glycan-costumed virus-like particles promote type 1 anti-tumor immunity: https://bit.ly/49UWxdrLaura's Twitter: https://twitter.com/ChemicalBiology

Dr. Dionna Williams is an Acting Associate Professor in the Department of Pharmacology & Chemical Biology at Emory University. Their research focuses on the effects of HIV infection on the brain. She talks about how HIV affects immune cells in the brain and how this can lead to neuropsychiatric symptoms. They also discuss therapeutic approaches, factors that affect how drugs can reach the brain, and moving their lab to Atlanta.

What can we expect from GPCRs in antibodies and biologics? In this episode of The Chain, host Rajesh Sundaresan, PhD, Scientific Leader and GSK Fellow of Protein Cell and Structural Sciences at GlaxoSmithKline, speaks with Thomas P. Sakmar, MD, Professor of Chemical Biology at Rockefeller University, about the history of GPCRs and various subunits, his early work with rhodopsin, and the impact of crystallography and structural work. He also shares how he got started with molecular biology training, as well as his thoughts on the state-of-the art for both biologics and small molecules in drug discovery.  LINKS:    Rockefeller University: https://www.rockefeller.edu  GlaxoSmithKline: https://www.gsk.com/en-gb/   

Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely prescribed drug venetoclax, according to a recent study published in Cancer Discovery and led by scientists from Perlmutter Cancer Center at NYU Langone Health. Today on OncTimes Talk, we interview Dr. Christina Glytsou, lead author of the study, and discuss the reasons behind leukemia cells’ resistance to venetoclax, a BH3 mimetic drug that promotes cancer cell death in individuals with AML. Dr. Glytsou holds a joint appointment as an Assistant Professor in the Department of Chemical Biology at the Ernest Mario School of Pharmacy of Rutgers University and the Department of Pediatrics at Rutgers Robert Wood Johnson Medical School. She is a member of Cancer Metabolism & Immunology and the Cancer Pharmacology Programs, at the Cancer Institute of New Jersey. Dr. Glytsou’s laboratory aims to address fundamental questions unravelling the role of mitochondrial biology in blood malignancies’ progression and drug resistance.

Daniel Nocera, the Patterson Rockwood Professor of Energy, Department of Chemistry and Chemical Biology at Harvard University, talks about a biofertilizer that has the potential to revolutionize world agriculture and save energy in the process.

Ethan Karp — President and CEO of MAGNET: The Manufacturing Advocacy and Growth Network which, founded in 1984, has been dedicated to fostering local manufacturing and supporting local manufacturing businesses across technological innovation, workforce training and improved management practices.Ethan joined as CEO of MAGNET in 2013 after a consulting career at McKinsey & Co. and academic studies in biochemistry and physics and ultimately a Ph.D. in Chemical Biology from Harvard.We cover a lot in our conversation today — from Ethan's path to MAGNET, to MAGNET's Blueprint for Manufacturing and plan to fuel a true manufacturing revival in Northeast Ohio. We cover the rich industrious and manufacturing history of Northeast Ohio and prominence of manufacturing in the local economy today, the implications for automation on the future of manufacturing, the importance of apprenticeship programs, making manufacturing cool again, showcasing career paths for younger talent to join the industry, reshoring, upskilling and workforce shortages… and we cover what this work looks like in practice and examples of companies MAGNET has worked with, including some who's stories we've told on the show like Tom Lix of Cleveland Whiskey (Episode #21)!Ethan exudes a real passion for this work and is an involved community builder outside of MAGNET sitting on the boards of the Cleveland and Cuyahoga County Workforce Development, American Small Manufacturers Coalition, Cleveland Leadership Center, MidTown Cleveland, Inc., Cleveland Jewish Publication Company and the Jewish Education Center of Cleveland.I really enjoyed learning more about the state of manufacturing in Northeast Ohio and MAGNET's role in helping to impact its future — please enjoy my conversation with Ethan Karp!-----Lay of The Land is brought to you by Ninety. As a Lay of The Land listener, you can leverage a free trial with Ninety, the platform that helps teams build great companies and the only officially licensed software for EOS® — used by over 7,000 companies and 100,000 users!This episode is brought to you by Impact Architects. As we share the stories of entrepreneurs building incredible organizations throughout NEO, Impact Architects helps those leaders — many of whom we've heard from as guests on Lay of The Land — realize their visions and build great organizations. I believe in Impact Architects and the people behind it so much, that I have actually joined them personally in their mission to help leaders gain focus, align together, and thrive by doing what they love! As a listener, you can sit down for a free consultation with Impact Architects by visiting ia.layoftheland.fm!-----Connect with Ethan Karp on LinkedIn — https://www.linkedin.com/in/ethankarp/Learn more about MAGNET: The Manufacturing Advocacy and Growth Network — https://www.manufacturingsuccess.org/Follow MAGNET on Twitter @magnetohio — https://twitter.com/magnetohio-----For more episodes of Lay of The Land, visit https://www.layoftheland.fm/Past guests include Cleveland Mayor Justin Bibb, Steve Potash (OverDrive), Ed Largest (Westfield), Ray Leach (JumpStart), Lila Mills (Signal Cleveland), Pat Conway (Great Lakes Brewing), Lindsay Watson (Augment Therapy), and many more.Stay up to date on all our podcasts by signing up for Lay of The Land's weekly newsletter — sign up here.Connect with Jeffrey Stern on LinkedIn — https://www.linkedin.com/in/jeffreypstern/Follow Jeffrey Stern on Twitter @sternJefe — https://twitter.com/sternjefeFollow Lay of The Land on Twitter @podlayofthelandhttps://www.jeffreys.page/

Dr. Laura Kiessling is the Novartis Professor of Chemistry at Massachusetts Institute of Technology (MIT) and Member of the Broad Institute. Laura's research focuses on carbohydrates, particularly all of the different carbohydrates found on the surfaces of cells. We still know relatively little about the functions of these carbohydrates, and Laura is eager to learn more. When she's not doing science, Laura likes being active through rowing, kayaking, cycling, lifting weights, or doing yoga. She also likes to spend her free time cooking, hiking, camping, and enjoying art. She received her BS degree in chemistry from MIT and her Ph.D. degree in organic chemistry from Yale University. After two years at the California Institute of Technology as an American Cancer Society Postdoctoral Fellow, she joined the faculty of the University of Wisconsin, Madison in 1991. She returned to MIT in 2017. Laura has received numerous awards over the course of her career, including the Ronald Breslow Award in Biomimetic Chemistry, the Centenary Prize from the Royal Society of Chemistry, the Tetrahedron Prize for creativity in Organic Chemistry or Bioorganic & Medicinal Chemistry, the Gibbs Medal, from the Chicago Chapter of the American Chemical Society, the Vilas Distinguished Faculty Award from UW-Madison, and others. Laura is an elected Member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Microbiology, and the American Academy of Arts & Sciences, and American Philosophical Society, as well as an elected Fellow of the American Association for the Advancement of Science. She has been awarded a Guggenheim Fellowship, an American Cancer Society Fellowship, a MacArthur Foundation Fellowship, and an Alfred P. Sloan Foundation Fellowship. She is also the founding Editor-In-Chief of the journal ACS Chemical Biology. In this interview, Laura shares more about her life and science.

Joining us today at Maximal Being Fitness, Nutrition, and Gut Health, is Dr. Mokenge Malafa. He continues to work in research and is a Senior Member in the Department of Gastrointestinal Oncology and the Chemical Biology and Molecular Medicine Program at Moffitt Cancer Center. As a physician-scientist, he is enthusiastically investigating novel approaches to prevent pancreatic cancer and colorectal cancer. Topics- Doc Mok an advanced GI doctor specializing in nutrition, gut health, and cancer. Joining him is the podcast's layman, Jacky P, smashing the broscience on this week's podcast. Their guest Dr. Mokenge Malafa is a physician-scientist who specializes in minimally invasive robotic surgery for gastrointestinal cancers. He also conducts research investigating novel approaches to prevent pancreatic and colorectal cancers. If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a difference Reach out to us at team@maximalbeing.comOr https://www.maximalbeing.com/site/contact 5 FREE Gut Health Hacks (that your doctor won't tell you)5 Days of FREE videos delivered straight to your inbox.No obligation other than your email. I promise I won't send you constant useless garbage emails.*Plus we will send you an extra surprise*https://www.maximalbeing.comSocialFacebook: https://www.facebook.com/maximalbeing/ Twitter: https://twitter.com/maximalbeing Instagram: https://www.instagram.com/maximalbeings/ Pinterest: https://www.pinterest.com/maximalbeing/ Linked'in: https://www.linkedin.com/in/maximal-being-13a5051a1/ YouTube: https://www.youtube.com/channel/UCi7KVUF8U-gfhOE1KSNAqIg #MaximalBeing #DocMok #DrMalafa

Here in Episode 17, podcast host Dr. Jerry Workman speaks with Dr. Jake Shelley about the latest developments and research in the field of atomic spectroscopy. Dr. Jake Shelley is the Alan Paul Schulz Professor of Chemistry in the Department of Chemistry and Chemical Biology at Rensselaer Polytechnic Institute (RPI) in Troy, New York. Shelley's research explores new hardware and software tools for mass spectrometry for improved detection and identification of analytes, particularly in complex matrices. He is an emerging leader in the field of atomic spectroscopy as noted by his academic background, and involvement with journals, conferences, and by multiple awards, publications, and patents. More information and links about Prof. Shelley and his research can be found within our podcast postings.

Joining us today at Maximal Being Fitness, Nutrition, and Gut Health, is Dr. Mokenge Malafa. He continues to work in research and is a Senior Member in the Department of Gastrointestinal Oncology and the Chemical Biology and Molecular Medicine Program at Moffitt Cancer Center. As a physician-scientist, he is enthusiastically investigating novel approaches to prevent pancreatic cancer and colorectal cancer. Topics - The field of transcriptional regulation and transcription factors.- Water-soluble and fat-soluble vitamins- The Two Kinds of Vitamin E Doc Mok an advanced GI doctor specializing in nutrition, gut health, and cancer. Joining him is the podcast's layman, Jacky P, smashing the broscience on this week's podcast. Their guest Dr. Mokenge Malafa is a physician-scientist who specializes in minimally invasive robotic surgery for gastrointestinal cancers. He also conducts research investigating novel approaches to prevent pancreatic and colorectal cancers. If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it really makes a difference Reach out to us at team@maximalbeing.comOr https://www.maximalbeing.com/site/contact FREE STUFF3 NUTRITION HACKS (that Your Doctor Won't Tell You) FREE e-book: https://www.maximalbeing.com/3-nutrition-hacksThe Perfect Human Diet: A FREE 5 part training video: https://www.maximalbeing.com/the-perfect-human-diet WE CAN HELP YOUSign-up for our Kombucha Course: https://www.maximalbeing.com/kombuchaThe Meal Prep Bootcamp Course: https://www.maximalbeing.com/offers/oGLXwoof/checkoutNeed a Sustainable Nutrition Solution for Gut Health: https://www.maximalbeing.com/sustainable-nutrition-solution Our sponsorsEmerson Ecologics (10% OFF All Supplements): https://wellevate.me/maximal-beingiHerb supplement BDB5528 and receive 10% off your orders: https://www.maximalbeing.com/iherb Resourceshttps://www.maximalbeing.com SocialFacebook: https://www.facebook.com/maximalbeing/Twitter: https://twitter.com/maximalbeingInstagram: https://www.instagram.com/maximalbeings/Pinterest: https://www.pinterest.com/maximalbeing/Linked'in: https://www.linkedin.com/in/maximal-being-13a5051a1/YouTube: https://www.youtube.com/channel/UCi7KVUF8U-gfhOE1KSNAqIg #MaximalBeing #DocMok #DrMalafa

Episode 77. Jun Axup is Chief Operating Officer at E11 Bio, a Focused Research Organization. She is an entrepreneur and former Chief Scientific Officer and Partner at IndiBio. She's also a musician, artist, and community builder. Jun completed her PhD in Chemical Biology at Scripps Research. Check out some of her awesome projects at her personal website: https://junaxup.com/

Dan Nomura  is a distinguished professor at UC Berkeley and an Investigator at the Innovative Genomics Institute, specializing in Chemical Biology and Molecular Therapeutics. He serves as the Director of the Novartis-Berkeley Translational Chemical Biology Institute and founded Frontier Medicines and Vicinitas Therapeutics. He's also a16z Bio+Health's newest advisory partner.In this episode, Dan joins general partner Jorge Conde and investment partner Becky Pferdehirt to discuss how he got started working in chemical biology and chemoproteomics and his  experience founding companies, along with leading lab and pharma collaborations.

In today's episode we plunge into the intriguingly murky world with the profound Professor David B. Collum. Aptly titled, "Hello Darkness: A Chilling Journey into the Abyss" it's a captivating journey through a labyrinth of contentious topics, from scandalous political intrigues to the convoluted realities of climate change, gender transition and directed energy weapons.  Collum, armed with his razor-sharp intellect and unique perspectives, serves as our guide, steering us through this dark maze, sparking intense and thought-provoking discussions. Dave doesn't care if he comes across as an asshole. He really doesn't. He's just trying to get it right. Dr. David B. Collum, MA, MS, Ph.D. is a Professor at The Cornell University. He received a Doctor of Philosophy from Columbia University in the City of New York. His research interests are Chemistry and Chemical Biology, Physical Organic Chemistry, Organolithium Chemistry, Organosodium Chemistry, Kinetics, Reaction Mechanism. This episode is brought to you by River. With 100% full reserve custody and zero fees on recurring orders, River allows you to buy and mine Bitcoin with ease. Plus, River offers unparalleled service and functionality, including tax optimization, entity accounts, inheritance planning and instant buy volume.  Use this link (River) to get started and get $5 in BTC when you buy Bitcoin at River. For the ultimate in Bitcoin security and design, check out the COLDCARD hardware wallet from Coinkite. With built-in sleep-at-night technology, it's the only dedicated air-gapped, ultra-secure hardware wallet for Bitcoin.  Coinkite is a leader in security and hardware manufacturer, est. block 141,000. Maker of some of the most iconic Bitcoin products, such as OPENDIME, COLDCARD, BLOCKCLOCK, SATSCARD, TAPSIGNER and SATSCHIP. For a discount use this link: https://store.coinkite.com/promo/B81AD35FE804254094F9 Follow Dr. David B Collum on Twitter: @DavidBCollum Follow Cedric Youngelman on Twitter: @CedYoungelman Follow the Bitcoin Matrix Podcast on Twitter: @_BitcoinMatrix

Dave takes you down the darkest goddamn hole he's ever gone down. In this captivating three-hour rip, Dr. David B. Collum and I explore the perplexing question of how individuals can be led to make decisions that ultimately prove self-destructive and antithetical to their own interests and values. Dr. David B. Collum, MA, MS, Ph.D. is a Professor at The Cornell University. He received a Doctor of Philosophy from Columbia University in the City of New York. His research interests are Chemistry and Chemical Biology, Physical Organic Chemistry, Organolithium Chemistry, Organosodium Chemistry, Kinetics, Reaction Mechanism. With Dave's background in Austrian economics and his vast knowledge of history, he offers a unique perspective that will leave you questioning the world around you. Strap in, open your mind, and prepare to embark on a journey that will challenge your beliefs and expand your understanding of history's lessons in the Great Bamboozle with Professor David B Collum. This episode is brought to you by River. With 100% full reserve custody and zero fees on recurring orders, River allows you to buy and mine Bitcoin with ease. Plus, River offers unparalleled service and functionality, including tax optimization, entity accounts, inheritance planning and instant buy volume.  Use this link (River) to get started and get $5 in BTC when you buy Bitcoin or miners at River. For the ultimate in Bitcoin security and design, check out the COLDCARD hardware wallet from Coinkite. With built-in sleep-at-night technology, it's the only dedicated air-gapped, ultra-secure hardware wallet for Bitcoin.  Coinkite is a leader in security and hardware manufacturer, est. block 141,000. Maker of some of the most iconic Bitcoin products, such as OPENDIME, COLDCARD, BLOCKCLOCK, SATSCARD, TAPSIGNER and SATSCHIP. For a discount use this link: https://store.coinkite.com/promo/B81AD35FE804254094F9 Network with fellow Bitcoiners in Austin, Texas. August 24th, 25th, 26th, and 27th, 2023.  BITBLOCKBOOM IS NOT A SHITCOIN, NFT OR BLOCKCHAIN EVENT. Join is for the 6TH YEAR AS WE TALK ABOUT BITCOIN! The last weekend in August. Gary Leland who's been on the show twice for two fantastic conversations has rented an entire town for the welcome party that Thursday night. GRAB YOUR SPOT NOW Use the code Matrix or the link in the show notes for a 10% discount on your tickets at https://bitblockboom.com/?coupon=matrix Follow Dr. David B Collum on Twitter: @DavidBCollum Follow Cedric Youngelman on Twitter: @CedYoungelman Follow the Bitcoin Matrix Podcast on Twitter: @_BitcoinMatrix

Dr. Antoine van Oijen is a Distinguished Professor and Australian Research Council Laureate Fellow in the School of Chemistry at the University of Wollongong in Australia. The work Antoine does combines physics, chemistry, and biology. He develops new types of microscopes to visualize complex biochemical reactions at the level of individual molecules. In particular, his group is interested in how DNA is copied before a cell divides. Antoine is also doing research examining how bacteria acquire antibiotic resistance. Antoine and his family enjoy spending much of their free time exploring the beautiful beach and hiking in the wonderful parks nearby. Antoine received his MSc and PhD in Physics from Leiden University in the Netherlands, where his graduate work was recognized with the C.J. Kok prize for best doctoral thesis. Afterwards, he conducted postdoctoral research in Chemistry and Chemical Biology at Harvard University. Antoine served on the faculty at Harvard Medical School and Groningen University in the Netherlands before his recent move to the University of Wollongong where he is today. Antoine has received a wide array of honors and awards for his research, including the Armenise-Harvard Junior Faculty Award, a Searle Scholarship, a NSF CAREER Award, a Vici Award from the Dutch Science Foundation, the Dutch Society for Biochemistry and Molecular Biology Award for the most promising young scientist, and the prestigious Australian Research Council Laureate Fellowship. In this episode, Antoine discusses his research and his journey through life and science.

On this episode, I was joined by Rumi Young, Director of Regulatory Policy at Beckton Dickinson(BD). Rumi walks through: Connected Devices and Combination Products How Regulators approach regulating new technologies Traceability Technologies and what they mean for manufacturing and use Comparability Protocols and Pre-Determined Change Controls for Drugs and Devices Rumi Young, Meng, RAC is the Director of Regulatory Policy at Becton Dickinson (BD). In this role she leads a team that advances policies to speed time to market, promote innovation and ensure reasonable regulatory requirements for medical devices, diagnostics and combination products. Rumi joined BD from FDA where she spent four years in CDRH's Division of Drug Delivery, General Hospital and Human Factors. As Acting Assistant Director for Injection Devices, her team was responsible for the approval of drug delivery injection devices and combination products such as syringes, auto injectors, pen injectors, on-body injectors and smart connected devices. Prior to FDA Rumi worked at Genentech and AstraZeneca for eight years in combination product development. Rumi has both a Bachelors in Chemistry and Chemical Biology and Masters in Engineering in Material Science from Cornell University.

David Liu is a professor in the Department of Chemistry and Chemical Biology at Harvard University. Liu's lab has introduced breakthrough technologies to the field of genome editing, including base editing and prime editing, with the aim of treating genetic diseases. In their latest work, his research team took a “no stone unturned” approach to determine a one-time base editing strategy to treat the motor neuron disease, spinal muscular atrophy (SMA). In this episode, Deanna MacNeil from The Scientist's Creative Services Team spoke with Liu to learn more about his philosophy of science, which involves an appreciation of fundamental principles in chemistry and evolution. Science Philosophy in a Flash is a series of mini podcasts produced by The Scientist's Creative Services Team. With a focus on the people behind the science, this podcast highlights researchers' unique outlook on what motivates their pursuit of science and what it means to be a scientist.

Dr. Mary Jo Ondrechen is Professor of Chemistry and Chemical Biology at Northeastern University. In the lab, Mary Jo uses theory and computation to better understand how molecules work. In particular she works on enzymes which are proteins that catalyze chemical reactions. Mary Jo and her team also develop methods and theories to interpret genomic data, and they work on the computational side of drug discovery, helping medicinal chemists develop new drugs, treatments, and diagnostics. When she's not at work, you can often find Mary Jo out running, tending to her vegetable garden, and cooking. She is also interested in herbs, spices, and medicinal plants. She earned her bachelor's degree in Chemistry from Reed College, and she was awarded her PhD in Chemistry and Chemical Physics from Northwestern University. Afterwards, Mary Jo completed a postdoctoral fellowship at the University of Chicago and subsequently a NATO Postdoctoral Fellowship at Tel-Aviv University in Israel. She joined the faculty at Northeastern University in 1980. Mary Jo was awarded the Outstanding Native American Student Mentor in 2018 from the Society for Advancement of Chicanos/Hispanics & Native Americans in Science (SACNAS), and she has been dedicated to advocacy and activism for underrepresented communities in science and society, as well as conservation and stewardship of the Earth. In our interview, she shares more about her life and science.

David Liu is the Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, the Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University, and a Howard Hughes Medical Institute (HHMI) investigator. Liu's research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors and prime editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing—the first general method to perform precision gene editing without double-stranded breaks, and a Science 2017 Breakthrough of the Year finalist—as well as prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. These technologies are used by thousands of labs around the world and have enabled the study and potential treatment of many genetic diseases. Four base editing clinical trials are already underway to treat leukemia, hypercholesterolemia, beta-thalassemia, and sickle-cell disease, with the first base editing clinical readout occuring last December, when it was announced that Alyssa, a 13-year-old girl in the UK, was cleared of T-cell leukemia by receiving triply base-edited CAR-T cells.Liu graduated first in his class at Harvard College in 1994. During his doctoral research at UC Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his PhD in 1999 and became assistant professor of chemistry and chemical biology at Harvard University in the same year. He was promoted to associate professor in 2003 and to full professor in 2005.Liu became a Howard Hughes Medical Institute investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. In 2016 he became a Core Institute Member and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, and Director of the Chemical Biology and Therapeutics Science Program. Liu has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. He is the 2022 King Faisal Prize Laureate in Medicine.He is the founder or co-founder of several biotechnology and therapeutics companies, including Prime Medicine, Beam Therapeutics, Editas Medicine, Pairwise Plants, Exo Therapeutics, Chroma Medicine, Resonance Medicine, and Nvelop Therapeutics.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

On this episode, I was joined by Rumi Young, Director of Regulatory Policy at Beckton Dickinson(BD). Rumi walks through: How FDA Reviews Combination Products Industry's role in shaping policy Essential Performance Requirements IMDRF and International Harmonization Opportunities Rumi Young, Meng, RAC is the Director of Regulatory Policy at Becton Dickinson (BD). In this role she leads a team that advances policies to speed time to market, promote innovation and ensure reasonable regulatory requirements for medical devices, diagnostics and combination products. Rumi joined BD from FDA where she spent four years in CDRH's Division of Drug Delivery, General Hospital and Human Factors. As Acting Assistant Director for Injection Devices, her team was responsible for the approval of drug delivery injection devices and combination products such as syringes, auto injectors, pen injectors, on-body injectors and smart connected devices. Prior to FDA Rumi worked at Genentech and AstraZeneca for eight years in combination product development. Rumi has both a Bachelors in Chemistry and Chemical Biology and Masters in Engineering in Material Science from Cornell University.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jennifer Chadwick, CSO of ProtaGene. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jennifer, covering: Lessons and learnings moving from the world of academia into commercial industry The shift from lowest-price tactical outsourcing to value-based, holistic, and strategic outsourcing at a much earlier stage Nuances in the sandbox of playing with the buckets of CGTPs, and why emerging therapeutics do not play by the rules The increasing importance of risk-based assessment in early-stage drug development, and the need to increase the bar for understanding complex modalities in a smart, cost-effective and efficient way as we begin to understand them more Jennifer Chadwick is Chief Scientific Officer of ProtaGene and serves as Site Head in Boston. She brings two decades of experience leading scientific teams in the biotech industry and academia and is a well-recognized expert in development of biologics and gene therapy products. She served as Vice President of Analytical Development and of Biologic Development at BioAnalytix. Previously, Dr. Chadwick was a tenured Professor of Pharmaceutical Chemistry at the University of Kansas. Jen has authored thought leadership articles related to analytical development of gene therapy products and published approximately 75 peer-reviewed publications, 13 patents, and four book chapters, demonstrating her expertise and deep understanding of biologics and drug development. Dr. Chadwick has served as an Associate Director of CASSS and a member of the Steering Committee for academic-industry relations at the Massachusetts Biotechnology Council. She is also a Visiting Scholar in the Department of Chemistry and Chemical Biology at Northeastern University. She received her PhD from Purdue University Department of Chemistry. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

If you're human, I'm sure you've been stressed out at some point in time. Unfortunately, it is an inevitable occurrence during any stage of life. Not only does stress make you feel older, in a very real sense, it can speed up aging. But, what if you could reverse your increased aging following recovery from that stress? In this week's Everything Epigenetics podcast, Dr. Jesse Pognaik speaks with me about just that. We take a deep dive into his study which focuses on Biological Age being increased by stress and if it can be restored upon recovery. First, we discuss possible fluctuations in Biological Age by using a mouse model of heterochronic parabiosis. Then, how Dr. Poganik and his team applied a suite of advanced epigenetic age clocks in humans and mice to measure reversible biological age changes in response to various stressful stimuli including trauma surgery in elderly patients, pregnancy, and severe COVID-19. This incredible study uncovers a new layer of aging dynamics which should be considered in future studies. Furthermore, elevation of biological age by stress may be a quantifiable and actionable target for future interventions. Dr. Poganik is now actively working on answering the question, “Which clocks are actually measuring biological aging?”, as the current models do not discriminate between casual methylation changes. In this podcast you'll hear:The definition of stress in the context of Jesse's paperHeterochronic parabiosis defined and explainedThe connection between severe stress and aging using Biological Age clocksHow unexpected surgeries and elected surgeries affect Biological Age Improvement of Biological Age after surgeriesHow pregnancy affects Biological AgePregnancy and the connection to parabiosis The peak risks at the time of delivery of pregnancy in mice and human systems Recovery of Biological Age after pregnancySevere COVID-19 and the effects on Biological AgingPartial recovery upon COVID-19 patients after being discharged The need to study long COVID-19 How Dr. Poganik decided upon the stressors of interest The suite of Epigenetic Clocks used in the studyFirst generation clocks vs. second generation clocksThe precision of Epigenetic ClocksPrincipal component analysis algorithms The future of DNA methylation (DNAm) clocksThe need to understand which clocks measure what What is aging? Dr. Jesse Poganik Jesse Poganik was born and raised in Queens, New York, USA. He received his B.S. in Chemistry from the State University of New York at Stony Brook and M.S. and Ph.D. degrees in Chemical Biology from Cornell University. In 2020, he began his postdoctoral training in Prof. Vadim Gladyshev's laboratory at Brigham and Women's Hospital, Harvard Medical School. Jesse's current focus is on understanding the fundamental biological nature of aging.Support the showThank you for joining us at the Everything Epigenetics Podcast and remember you have control over your Epigenetics, so tune in next time to learn more about how.

Ethan Karp, President and CEO of MAGNET sheds light on the different pillars of innovation and emphasizes the critical importance of people and talent in driving successful innovation. As a millennial CEO, Ethan also shares his insights on navigating the current work culture and leveraging the strengths of a diverse and dynamic team.  More about our guest:Dr. Ethan Karp is an expert in transforming companies and communities. He's a committed change-maker and community builder: Board Chair of the Cleveland/Cuyahoga County Workforce Development, and serves as a Director on the boards of; the American Small Manufacturers Coalition, the Cleveland Leadership Center, MidTown Cleveland, Inc., Cleveland Jewish Publication Company and the Jewish Education Center of Cleveland. Dr. Karp is a recognized thought leader on manufacturing issues and a frequent media commentator on the future of manufacturing in America. Prior to joining MAGNET in 2013, Dr. Karp worked with Fortune 500 companies at McKinsey & Co. He received undergraduate degrees in biochemistry and physics from Miami University and a Ph.D. in Chemical Biology from Harvard University. Dr. Karp lives in Cleveland with his wife and three young girls.------------------------------------------------Episode Guide:1:46 - What is innovation?5:07 - Four buckets of technology6:53 - Technology and Innovation: The people (talent) side8:52 - Technology and Innovation: The company side9:57 - Technology and Innovation: Culture11:50 - Assessing Risk Profiles16:49 - Case Study: Giant Red Barn of Cleveland20:35 - What isn't innovation?  25:26 - Continuum in innovation28:40 - Philosophy of leadership  31:14 - Advice for innovators-------------------------OUTLAST Consulting offers professional development and strategic advisory services in the areas of innovation and diversity management.

MPF Discussion with Marie LesaicherreHow Purpose And meaning Get Us Through The Tough Times with Marie LesaicherreMarie Lesaicherre, PhD, MBA, is the founder and CEO of Akesa Health, a startup offering a self-guided therapy app helping people transform anxiety and distress into resilience. She is a global entrepreneurial executive with 18 years' experience launching tech businesses for General Electric and startups in the US, Asia, Europe, Africa, and the Middle East. Marie holds a PhD in Chemical Biology from the National University of Singapore and an executive MBA from Columbia Business School and the London Business School.  On this episode of My Perfect Failure (How Purpose And meaning Get Us Through The Tough Times) I have an inspiring and insightful conversation with Marie.  Marie reveals how her life which was littered with academic achievements along with professional achievements and career progression. Marie explains although she had all this success, it masked significant trauma that came to the surface and stopped her in her tracks.Ultimately dealing with this trauma took Marie on a difficult journey which resulted in her discovering purpose and meaning where today she is supporting people globally with their health challenges with her health app Akesa Health. Contact MarieContact Marie at Akesa·       https://www.akesahealth.com Connect with Marie on LinkedIn·       https://www.linkedin.com/in/drlesaicherre/ Follow Akesa Health on LinkedIn ·       https://www.linkedin.com/company/akesahealth Follow Akesa Health on Twitter·       https://twitter.com/AkesaHealth Follow Akesa Health on Facebook·       https://www.facebook.com/akesahealth Follow Marie on Medium·       https://medium.com/@DrLesaicherre Read Marie's Article: EMDR saved My Life ·       https://medium.com/@DrLesaicherre/emdr-saved-my-life-6878189a5f68 The Philosophy of iKigal: 3 Examples About Finding Purpose·       https://positivepsychology.com/ikigai/    Please Leave A Review Like this show? Please leave us a review here, even one sentence helps! Consider including your Twitter handle so we can thank you personally! Paul: Contact Details   ·         Work with me: paul@myperfectfailure.com ·         MPF Website: http://www.myperfectfailure.com/  ·         Insta: follow: https://www.instagram.com/myperfectfailure/   ·         Twitter: https://twitter.com/failure_perfect  ·         Facebook MPF Private Group:  https://www.facebook.com/groups/377418129517757 

As part of the US HUPO sponsored "Road to Chicago" series highlighting speakers at the upcoming US HUPO meeting in Chicago in 2023, Ben and Ben sit down to talk with Dr. Alexander Ivanov from the Barnett Institute of Chemical and Biological Analysis and the Department of Chemistry and Chemical Biology at Northeastern University.

Michelle Manni, PhD, assistant professor of Pharmacology and Chemical Biology at the University of Pittsburgh School of Medicine, discusses challenges often faced by women in academic research or medicine and what institutions can do to support women leaders in this space.

Marie Lesaicherre, PhD, MBA, is the founder and CEO of Akesa Health, a startup offering a self-guided therapy app helping people transform anxiety and distress into resilience. She is a global entrepreneurial executive with 18 years experience launching tech businesses for General Electric and startups in the US, Asia, Europe, Africa, and the Middle East. Marie holds a PhD in Chemical Biology from the National University of Singapore and an executive MBA from Columbia Business School and the London Business School. To learn more about Dr. Lesaicherre and Akesa Health, check out the following links: Akesa Health's Website and App (available on App Store): https://www.akesahealth.com/ Dr. Lesaicherre's Email: hello@akesahealth.com Akesa Health's Facebook: https://www.facebook.com/akesahealth Akesa Health's LinkedIn: https://www.linkedin.com/company/akesahealth/about/ LinkedIn: https://www.linkedin.com/in/drlesaicherre/ Akesa Health's Twitter: https://twitter.com/AkesaHealth

In the Best Of episode, we look back at Dan Wideaier of Bolt Threads. Dan Widmaier is a bioengineer who's taking on the fashion and beauty industries. As the Co-Founder and CEO of Bolt Threads, he's ushering in a new era of regenerative lab grown materials that can help us reverse course when it comes to the health of our planet. In this episode Dan and I talked about the science behind Bolt Threads' patented materials, and how they're being adopted by big brands like Stella McCartney and Adidas. In what was a fascinating conversation, I heard about his growth strategy, how industry disruption can be used to create social and environmental impact, and why companies that don't adopt regenerative practices could face existential problems. Dan Widmaier Dan has carefully tended Bolt's growth since 2009, using his passion and expertise to lead the company through technology development, expansion, and financing. He earned his Ph.D. in Chemistry and Chemical Biology from UC San Francisco, where his graduate research involved designing genetic circuits to control microbial organelles. Dan has grown Bolt Threads from an incubator start-up to a biomaterials platform company with 75 employees. He has led Bolt Threads through multiple fundraising rounds, created lasting partnerships with iconic global brands like Stella McCartney, and launched commercially available materials including MyloTM – a mycelium-based leather alternative – with a select group of partners including adidas, Kering, lululemon, and Stella McCartney.   This episode of Lead With We was produced and edited by Goal 17 Media and is available on Apple Podcasts, Google Podcasts, and Spotify. You can also watch episodes on YouTube at WeFirstTV.   Resources Learn more about Bolt Threads at boltthreads.com Connect with Dan on LinkedIn For case studies and other free resources about purposeful business, go to WeFirstBranding.com Simon's new book, Lead With We, comes out Nov. 9th and is now available for pre-order on Amazon, Google Books and Barnes & Noble. Check it out!

Dave joins me to talk his year in review, diet, Covid, Ukraine, the economy, the media, politics and more. David B. Collum is an economic commentator, chemist, Betty R. Miller Professor of Chemistry and Chemical Biology at Cornell University. He holds a PhD, Columbia University, MS, Columbia University, MA, Columbia University and BS, Cornell University. YouTube does not let me monetize my videos on the site and the podcast is full time work which will never have ads in the middle of it. If you enjoy the content, please support the QTR Podcast in any or all of the following ways: A small recurring donation via: Patreon: https://www.patreon.com/QTRResearch One time donations can also be sent via: Paypal: https://www.paypal.me/qtrresearch QTR MERCH is available here. You can also follow me on YouTube, and Twitter. And check out my new near-daily column, FRINGE FINANCE, at http://quoththeraven.substack.com THANK YOU TO ALL OF MY KIND PATRONS.    Please show love to those who support the QTR Podcast:  Masterworks - invest in art, skip the waitlist with code: QTR JM Bullion - where QTR buys gold & silver - Twitter: @JMBullion Doomberg - Subscribe 100% free - Twitter: @DoomburgT George Gammon - Rebel Capitalist Pro - Twitter: @GeorgeGammon Sang Lucci & Wall St. Jesus — The Steamroom — Twitter: @wallstjesus and @sanglucci Longest Running Supporters   Max Mulvihill - Since 2/2018  Mark Heywood - Since 3/2018 Kyle Thomas - Since 4/2018  Chris Bede - Since 5/2018  Dariusz Kordonski - Since 5/2018  Chris Gerrard - Since 5/2018 Shear Luck - Since 5/2018   Founding Members Of My "FRINGE FINANCE" Column Kashumba - Since 8/2021 Randy Carder - Since 8/2021 T Gaggiotti - Since 8/2021 Jamie - Since 8/2021 A Farmer - Since 9/2021 Harvest Moon Research - Since 9/2021 John H. H. - Since 11/2021 Mark Hutchinson - Since 11/2021 Joseph K. H. - Since 10/2021 A Farmer - Since 9/2021 Tsniezyk - Since 9/2021 Chris - Since 12/2021 All podcast content is subject to this disclaimer.    Chris is not an investment adviser. Listeners should always speak to their personal financial advisers. Please leave me alone.

Dr. Derek Lowe is a medicinal chemist, author, and blogger. He is currently Director in Chemical Biology and Therapeutics at the Novartis Institutes for Biomedical Research (NIBR). Dr. Lowe's work in drug discovery has spanned multiple decades with tenures at Schering-Plough, Bayer, and Vertex Pharmaceuticals. In addition to his industry work, Dr. Lowe authors a popular blog covering topics in drug discovery; check it out here: In the Pipeline.

In this episode of Chasing the Insights, I talk to inspirational entrepreneur and mental health advocate Marie Lesaicherre. Marie talks to us about the importance of mental health, especially for entrepreneur. Marie Lesaicherre is the founder and CEO of Akesa Health, a startup offering a self-guided therapy app helping people transform anxiety and distress into resilience without needing a therapist. She is a global entrepreneurial executive with 18 year-experience launching tech businesses for General Electric and startups in the US, Asia, Europe, Africa, and the Middle East. Marie holds a PhD in Chemical Biology from the National University of Singapore and an executive MBA from Columbia Business School and the London Business School.

In this episode Cedric sits down with Professor David B. Collum of Cornell University to shoot the sh*t about everything and to find out exactly how much nothing in society adds up anymore. Dr. David Collum, MA, MS, Ph.D. is a Professor at The Cornell University. He received a Doctor of Philosophy from Columbia University in the City of New York. His research interests are Chemistry and Chemical Biology, Physical Organic Chemistry, Organolithium Chemistry, Organosodium Chemistry, Kinetics, Reaction Mechanism. This podcast is brought to you by River Financial.  Get $20 free when you sign up for River and purchase Bitcoin, and up to $10,000 free when you purchase miners. Build your Bitcoin wealth at River today at: partner.river.com/matrix What if you didn't have to pay healthcare premiums anymore? What if you could invest in bitcoin instead? Pay one low monthly total to fund an account that is YOURS.  Choose your doctors, get great healthcare, and hold up to 75% of the balance in Bitcoin every month. Stop supporting the broken health insurance system with your hard-earned capital.  Go to joincrowdhealth.com and use code MATRIX now and experience freedom from health insurance by utilizing Bitcoin Right now you can get your first six months for just $99 per month. That's just a fraction of high deductible insurance plans Go to joincrowdhealth.com and use code MATRIX to sign-up. That's joincrowdhealth.com promo code MATRIX. CrowdHealth is not health insurance. It's a totally different way of paying for healthcare. Terms and Conditions may apply. Make sure to search for Bitcoin Matrix in your podcast app and click subscribe! And if you have the time please leave a review whereever you listen. Check the Bitcoin Matrix out on Fountain here: https://fountain.fm/show/8jJhCIKzojSARTePnCxM Subscribe to the Bitcoin Matrix on YouTube at tinyurl.com/bitcoinonyoutube Follow Professor David Collum on Twitter: @DavidBCollum Follow Cedric Youngelman on Twitter: @CedYoungelman Follow the Bitcoin Matrix Podcast on Twitter: @_BitcoinMatrix

On August 3rd, Senate Republicans held a hearing examining gain of function research: its possible role in creating the COVID-19 pandemic; the problems with oversight of this dangerous research; and recommendations to Congress for how to fix those problems. Episode Transcript Please Support Congressional Dish – Quick Links Contribute monthly or a lump sum via PayPal Support Congressional Dish via Patreon (donations per episode) Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536. Please make checks payable to Congressional Dish Thank you for supporting truly independent media! Watch Jen's Interview on CSPAN!!! Background Sources Gain-of-function Research Talha Burki. Feb 1, 2018. “Ban on gain-of-function studies ends.” The Lancet Infectious Diseases 18(2): pp 148-149. “Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens.” 2017. U.S. Department of Health and Human Services. Michael J. Selgelid. Aug 8, 2016. “Gain-of-Function Research: Ethical Analysis.” Science and Engineering Ethics 22(4): pp 923-964. Sara Reardon. October 22, 2014. “US suspends risky disease research.” Nature 514: pp 411-412. “Doing Diligence to Assess the Risks and Benefits of Life Sciences Gain-of-Function Research.” Oct 17, 2014. The White House Blog. Board on Life Sciences; Division on Earth and Life Studies; Committee on Science, Technology, and Law; Policy and Global Affairs; Board on Health Sciences Policy; National Research Council; Institute of Medicine. April 13, 2015. “Potential Risks and Benefits of Gain-of-Function Research: Summary of a Workshop.” National Academies Press. Marc Lipsitch. Jun 29, 2014. “Anthrax? That's Not the Real Worry.” The New York Times. COVID-19 Origin Theories Gary Ruskin. Sep 14, 2022. “Key articles on origins of Covid-19, gain-of-function research and biolabs.” U.S. Right to Know. Alina Chan. Jul 30, 2022. “The evidence for a natural vs lab origin of Covid-19.” Medium. Maria Cheng and Janey Keaten. Jun 9, 2022. “WHO: COVID origins unclear but lab leak theory needs study.” AP News. “WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO): preliminary report.” Jun 9, 2022. World Health Organization. Carl Zimmer and James Gorman. Updated Oct 13, 2021. “A Group of Scientists Presses a Case Against the Lab Leak Theory of Covid.” The New York Times. Richard Muller and Steven Quay. Oct 5, 2021. “Science Closes In on Covid's Origins.” The Wall Street Journal. Steven Quay and Richard Muller. Jun 6, 2021. “The Science Suggests a Wuhan Lab Leak.” The Wall Street Journal. “TWiV 762: SARS-CoV-2 origins with Robert Garry.” May 30, 2021. This Week in Virology [Podcast]. Glenn Kessler. May 25, 2021. “Timeline: How the Wuhan lab-leak theory suddenly became credible.” The Washington Post. Jorge Casesmeiro Roger. Mar 24, 2021. “An Interview with Richard Ebright: The WHO Investigation Members Were ‘participants in disinformation.'” Independent Science News. Josh Rogin. Mar 8, 2021. “In 2018, Diplomats Warned of Risky Coronavirus Experiments in a Wuhan Lab. No One Listened.” Politico. Jane Qiu. Jun 1, 2020. “How China's ‘Bat Woman' Hunted Down Viruses from SARS to the New Coronavirus.” Scientific American. EcoHealth Alliance and Funding for Coronavirus Research Katherine Eban. March 31, 2022. “‘This Shouldn't Happen': Inside the Virus-Hunting Nonprofit at the Center of the Lab-Leak Controversy.” Vanity Fair. Sharon Lerner and Maia Hibbett. Sep, 23 2021. “Leaked Grant Proposal Details High-Risk Coronavirus Research.” The Intercept. Glenn Kessler. May 18, 2021. “Fact-checking the Paul-Fauci flap over Wuhan lab funding.” The Washington Post. Meredith Wadman and Jon Cohen. Apr 30, 2020. “NIH's axing of bat coronavirus grant a ‘horrible precedent' and might break rules, critics say.” Science. National Institutes of Health. May 27, 2014. NIH grant to EcoHealth Alliance for Wuhan research. NIH RePORTER. NIH Database Data Removal Amy Dockser Marcus. Jun 23, 2021. “Chinese Covid-19 Gene Data That Could Have Aided Pandemic Research Removed From NIH Database.” The Hearing Revisiting Gain of Function Research: What the Pandemic Taught Us and Where Do We Go From Here August 3, 2022 Senate Committee on Homeland Security and Governmental Affairs: Subcommittee on Emerging Threats and Spending Oversight Witnesses: Richard H. Ebright, Professor of Chemistry and Chemical Biology and Laboratory Director, Rutgers University Waksman Institute of Microbiology Testimony Steven Quay, CEO and Founder, Atossa Therapeutics, Inc. Testimony Kevin M. Esvelt, Associate Professor of Media Arts and Sciences, Massachusetts Institute of Technology Testimony Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

Welcome back to Season 3 of WISEcast! We are discussing how to take the right steps on a nonlinear career track. Our conversation features Stephanie Wisner, Co-founder at Centivax, Forbes 30 Under 30, and the author of Building Backwards to Biotech: the Power of Entrepreneurship to Drive Cutting-Edge Science to Market, which she wrote to help demystify the industry of biotech for those interested in entering or learning about it. (linked). In this episode, we learn how Stephanie chucked her 10 year career plan, when it's ok to change course, and how to plan your educational goals to allow for exploration and flexibility. Stephanie Wisner received her bachelor's in Chemistry & Chemical Biology from Cornell University and holds an MBA from University of Chicago, Booth School of Business. She combines her background in basic science with her experience in business to lead finance and operations for Centivax. You can connect to Stephanie Wisner on LinkedIn here: https://www.linkedin.com/in/stephanie-wisner-5aa4556a/ Support WIB x WISEcast here → Paypal, and to learn more about Young Women in Bio, visit www.womeninbio.org/ywib WISEcast is featured as the Top 45 Women in STEM Podcasts by Feedspot! Subscribe to The Wisest Children on YouTube and see how our young scientist proteges are making science accessible and fun through some STEM activities for kids! Visit our website thewisestwomen.com, and connect with us on: Instagram, Facebook, Twitter, YouTube, LinkedIn or by email at communityengagement@thewisestwomen.com. Episode Resources: https://www.theatlantic.com/sponsored/jpmc-2017/the-next-episode/1742/ https://online.maryville.edu/blog/non-linear-career-paths/#:~:text=Non%2Dlinear%20careers%20may%20begin,as%20unexpected%20opportunities%20present%20themselves. https://www.corporatecomplianceinsights.com/linear-vs-nonlinear-career-paths/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/thewisestwomen/message

New Yorkers in LA - do you feel the heat already on this topic or is it just the weather!?  This topic never gets old and there's so much to learn from those who call these places home as well as their fascinating stories. My guest today, @danielzahler started a movement to unite New Yorkers in Los Angeles. That's right, The New York Times picked up Daniel's unique, yet much needed community of New Yorkers, who have made the transition to Los Angeles and who have connected through a What's App group of 250 ppl (with a waitlist to join) called, NYC in LA.Why he started this community and more on what his New York & LA story is - you'll have to tune into the episode for that. However, what I can share is that Daniel has so many tips for both coasts along with pizza recommendations that will have you wanting to visit both cities to confirm. Daniel is a Harvard graduate in Chemistry & Chemical Biology, and has a JD from Harvard Law School. He even had a fellowship at Yale Medical School. He knows his east coast and is currently making his best life in the west coast while promoting a healthy lifestyle. Also did I mention, he not only offers multiple quotes on New York City, but he also shares a poem intertwining the city and Burning Man as one. Queue the heat and enjoy the episode!Please subscribe, rate, and review Gossipnista wherever you listen to your podcasts. Follow along on Instagram @GossipnistaPodcast to stay up-to-date on the latest about the podcast, episodes and exclusive content.Thank you for your support. Connect & learn more about Daniel Zahler below:Daniel's Newsletter - Vitamin Z Instagram - Daniel Zahler Instagram - NYC in LATwitterOther Resources for New Yorkers in LA: New York Times article on NYC in LA grouphttps://www.nytimes.com/2022/04/09/nyregion/whatsapp-new-yorkers-networking.htmlNYC in LA - Facebook grouphttps://www.facebook.com/groups/1035121456932178Article: How to Be Bicoastalhttps://medium.com/@danielzahler/how-to-be-bicoastal-818efa86079cArticle: Why I'm Moving to LAhttps://medium.com/@danielzahler/why-im-moving-to-la-f7ede9d5c189Article: How I Won LAhttps://medium.com/@danielzahler/how-i-won-la-and-you-can-too-b2808b1c74baHasidic Brooklyn tour - one of the coolest NYC experiences Daniel highly recommends https://abnb.me/zM4US5sxvqbXoxo, Gossipnista Support the show